CoChat

Tissue Kallikrein Mediates Pro-Inflammatory Pathways and Activation of Protease-Activated Receptor-4 in Proximal Tubular Epithelial Cells

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Tissue kallikrein (KLK1) expression is up-regulated in human diabetic kidney tissue and induced by high glucose (HG) in human proximal tubular epithelial cells (PTEC). Since the kallikrein-kinin system (KKS) has been linked to cellular inflammatory process in many diseases, it is likely that KLK1 expression may mediate the inflammatory process during the development of diabetic nephropathy. In this study, we explored the role of KLK1 in tubular pro-inflammatory responses under the diabetic milieu. Recombinant KLK1 stimulated the production of inflammatory cytokines in PTEC via the activation of p42/44 and p38 MAPK signaling pathways. Molecular knockdown of endogenous KLK1 expression by siRNA transfection in PTEC attenuated advanced glycation end-products (AGE)-induced IL-8 and ICAM-1 productions in vitro. Interestingly, exposure of PTEC to KLK1 induced the expression of protease-activated receptors (PARs). There was a 2.9-fold increase in PAR-4, 1.4-fold increase in PAR-1 and 1.2-fold increase in PAR-2 mRNA levels. Activation of PAR-4 by a selective agonist was found to elicit the pro-inflammatory and pro-fibrotic phenotypes in PTEC while blockade of the receptor by specific antagonist attenuated high glucose-induced IL-6, CCL-2, CTGF and collagen IV expression. Calcium mobilization by the PAR-4 agonist in PTEC was desensitized by pretreatment with KLK1. Consistent with these in vitro findings, there was a markedly up-regulation of tubular PAR-4 expression in human diabetic renal cortical tissues. Together, these results suggest that up-regulation of KLK1 in tubular epithelial cells may mediate pro-inflammatory pathway and PAR activation during diabetic nephropathy and provide a new therapeutic target for further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0088894

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Recombinant KLK1 induced both cytokine expression and MAPK activation in tubular cells. PTEC was incubated with 10-time PCR and ELISA respectively. KLK1 increased IL-6, CCL-2, IL-8 and ICAM-1 mRNA (A) and protein (B) expression. PTEC was incubated with 100 nM KLK1 for the indicated duration, and expression of MAPK signaling molecules was detected by Western blot analysis. KLK1 increased phosphorylated p38 (C) and phosphorylated p42/44 (D) MAPK signaling pathways. *p<0.05; ***p<0.001 compared with control.
Figure 1 Recombinant KLK1 induced both cytokine expression and MAPK activation in tubular cells. PTEC was incubated with 10-time PCR and ELISA respectively. KLK1 increased IL-6, CCL-2, IL-8 and ICAM-1 mRNA (A) and protein (B) expression. PTEC was incubated with 100 nM KLK1 for the indicated duration, and expression of MAPK signaling molecules was detected by Western blot analysis. KLK1 increased phosphorylated p38 (C) and phosphorylated p42/44 (D) MAPK signaling pathways. *p<0.05; ***p<0.001 compared with control.CC BY · PubMed Central
Figure 2 KLK1 mediated AGE-BSA induced IL-8 and ICAM-1 expression in PTEC. Cells were incubated with 0.1 or 0.5/ml AGE-BSA for 6 h, and gene expression was determined by real-time PCR analysis. AGE induced KLK1 mRNA expression in PTEC (A). Cells were transfected with KLK1-specific siRNA, and the endogenous protein level was determined by Western blot analysis (B). Transfected cells were incubated with 0.5 mg/ml AGE for 48 h, and protein expression of cytokine was detected in culture medium by ELISA. AGE -induced IL-8 (C) and ICAM-1 (D) protein expression was inhibited by KLK1 gene silencing. ***p<0.001 compared with control, δP<0.05 compared with mock transfection and #p<0.05; ##p<0.01 compared with mock transfection incubated with AGE.
Figure 2 KLK1 mediated AGE-BSA induced IL-8 and ICAM-1 expression in PTEC. Cells were incubated with 0.1 or 0.5/ml AGE-BSA for 6 h, and gene expression was determined by real-time PCR analysis. AGE induced KLK1 mRNA expression in PTEC (A). Cells were transfected with KLK1-specific siRNA, and the endogenous protein level was determined by Western blot analysis (B). Transfected cells were incubated with 0.5 mg/ml AGE for 48 h, and protein expression of cytokine was detected in culture medium by ELISA. AGE -induced IL-8 (C) and ICAM-1 (D) protein expression was inhibited by KLK1 gene silencing. ***p<0.001 compared with control, δP<0.05 compared with mock transfection and #p<0.05; ##p<0.01 compared with mock transfection incubated with AGE.CC BY · PubMed Central
Figure 3 Increased expression of PAR-4 by KLK1 and HG in PTEC. Cells were incubated with 10-time PCR analysis. KLK1 induced PAR-4 mRNA expression in a dose-dependent manner (A). Cells were incubated with 30 mM HG for the indicated duration, and gene expression of PARs was determined by real-time PCR analysis. HG induced PAR-1, PAR-2 and PAR-4 mRNA expression (B) and protein expression (C) in a time-dependent manner. *p<0.05; **p<0.01; ***p<0.001 compared with control.
Figure 3 Increased expression of PAR-4 by KLK1 and HG in PTEC. Cells were incubated with 10-time PCR analysis. KLK1 induced PAR-4 mRNA expression in a dose-dependent manner (A). Cells were incubated with 30 mM HG for the indicated duration, and gene expression of PARs was determined by real-time PCR analysis. HG induced PAR-1, PAR-2 and PAR-4 mRNA expression (B) and protein expression (C) in a time-dependent manner. *p<0.05; **p<0.01; ***p<0.001 compared with control.CC BY · PubMed Central
Figure 4 Representative immunohistochemical staining of PAR-1, PAR-2, PAR-3 and PAR-4 in human renal biopsies. Expression of PARs was demonstrated in renal tissue from patients with biopsy proven diabetic nephropathy (F–I) and non-diabetic control subjects (A–D). Isotype-matched negative control was shown in diabetic nephropathy section (J) and non-diabetic control (E). Magnification: 400X. Quantitative analysis of PAR staining by Image Pro Plus 6.0 software (K); IOD, Integrated Optical Density. **p<0.01; ***p<0.001 compared with control.
Figure 4 Representative immunohistochemical staining of PAR-1, PAR-2, PAR-3 and PAR-4 in human renal biopsies. Expression of PARs was demonstrated in renal tissue from patients with biopsy proven diabetic nephropathy (F–I) and non-diabetic control subjects (A–D). Isotype-matched negative control was shown in diabetic nephropathy section (J) and non-diabetic control (E). Magnification: 400X. Quantitative analysis of PAR staining by Image Pro Plus 6.0 software (K); IOD, Integrated Optical Density. **p<0.01; ***p<0.001 compared with control.CC BY · PubMed Central
Figure 5 Activation of PAR-4 by selective agonist induced pro-inflammatory and pro-fibrotic responses in PTEC. Cells were incubated with PAR-4 agonist AYPGKF-NH2 (AP4) for the indicated duration and doses, and gene and protein expression was determined by real-time PCR and ELISA respectively. PAR-4 agonist increased IL-6, CCL-2, IL-8 and ICAM-1 mRNA expressions in a dose- (A) and time- (B) dependent manner. PAR-4 agonist increased CTGF, but not TGFβ mRNA expression in a dose- (C) and time- (D) dependent manner. PAR-4 agonist induced IL-6, CCL-2, IL-8 and ICAM-1 protein secretion (E). *p<0.05; **p<0.01; ***p<0.001 compared with control.
Figure 5 Activation of PAR-4 by selective agonist induced pro-inflammatory and pro-fibrotic responses in PTEC. Cells were incubated with PAR-4 agonist AYPGKF-NH2 (AP4) for the indicated duration and doses, and gene and protein expression was determined by real-time PCR and ELISA respectively. PAR-4 agonist increased IL-6, CCL-2, IL-8 and ICAM-1 mRNA expressions in a dose- (A) and time- (B) dependent manner. PAR-4 agonist increased CTGF, but not TGFβ mRNA expression in a dose- (C) and time- (D) dependent manner. PAR-4 agonist induced IL-6, CCL-2, IL-8 and ICAM-1 protein secretion (E). *p<0.05; **p<0.01; ***p<0.001 compared with control.CC BY · PubMed Central
Figure 6 PAR-4 mediated HG-induced IL-6 and CCL-2 expression via p42/44 MAPK signaling in PTEC. Cells were pre-treated with 10 µM selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 30 mM HG. Western blot analysis showed an increase in phosphorylated p42/44 MAPK signaling by HG, which was partially inhibited by tcY-NH2 (A). HG-induced protein synthesis of IL-6 and CCL-2, detected by ELISA, was attenuated by tcY-NH2 (B). HG-induced CTGF and collagen IV up-regulation, detected by Western blot analysis, was attenuated by tcY-NH2 (C). *p<0.05; **p<0.01; ***p<0.001 compared with control and #p<0.05; ##p<0.01 compared with cells incubated with HG only.
Figure 6 PAR-4 mediated HG-induced IL-6 and CCL-2 expression via p42/44 MAPK signaling in PTEC. Cells were pre-treated with 10 µM selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 30 mM HG. Western blot analysis showed an increase in phosphorylated p42/44 MAPK signaling by HG, which was partially inhibited by tcY-NH2 (A). HG-induced protein synthesis of IL-6 and CCL-2, detected by ELISA, was attenuated by tcY-NH2 (B). HG-induced CTGF and collagen IV up-regulation, detected by Western blot analysis, was attenuated by tcY-NH2 (C). *p<0.05; **p<0.01; ***p<0.001 compared with control and #p<0.05; ##p<0.01 compared with cells incubated with HG only.CC BY · PubMed Central
Figure 7 Intracellular calcium mobilization by KLK1 and PAR-4 agonist in PTEC. Cells were incubated with Fluo-4 direct™ reagent solution at 37°C for 1 h and the fluorescence signals induced by the addition of recombinant KLK1 at the indicated concentrations were measured (A). Fluorescence signal induced by the addition of the PAR-4 agonist AYPGKF-NH2 (AP4) at the indicated concentrations (B). Fluorescence signal of PAR-4 agonist-induced calcium response in cross desensitization study. Cells were untreated or pretreated with 100 nM or 200 nM KLK1 for 10 min prior to AP4 stimulation (C). (↑) indicates the time at which agonist was added. Data are representative of three independent experiments.
Figure 7 Intracellular calcium mobilization by KLK1 and PAR-4 agonist in PTEC. Cells were incubated with Fluo-4 direct™ reagent solution at 37°C for 1 h and the fluorescence signals induced by the addition of recombinant KLK1 at the indicated concentrations were measured (A). Fluorescence signal induced by the addition of the PAR-4 agonist AYPGKF-NH2 (AP4) at the indicated concentrations (B). Fluorescence signal of PAR-4 agonist-induced calcium response in cross desensitization study. Cells were untreated or pretreated with 100 nM or 200 nM KLK1 for 10 min prior to AP4 stimulation (C). (↑) indicates the time at which agonist was added. Data are representative of three independent experiments.CC BY · PubMed Central
Figure 8 PAR-4 mediated KLK1-induced pro-inflammatory responses in PTEC. Cells were untreated or pre-treated with 10 µM of the selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 100 nM KLK1. Gene and protein expression was determined by real-time PCR and ELISA respectively. The increase of KLK1-induced CCL-2 and ICAM-1 mRNA expression was significantly attenuated by PAR-4 antagonist (A) and the increase of KLK-induced CCL-2, IL-8 and ICAM-1 protein expression was significantly reduced by PAR-4 antagonist (B). *p<0.05 compared with control and #p<0.05; ##p<0.01 compared with cells incubated with KLK1 only.
Figure 8 PAR-4 mediated KLK1-induced pro-inflammatory responses in PTEC. Cells were untreated or pre-treated with 10 µM of the selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 100 nM KLK1. Gene and protein expression was determined by real-time PCR and ELISA respectively. The increase of KLK1-induced CCL-2 and ICAM-1 mRNA expression was significantly attenuated by PAR-4 antagonist (A) and the increase of KLK-induced CCL-2, IL-8 and ICAM-1 protein expression was significantly reduced by PAR-4 antagonist (B). *p<0.05 compared with control and #p<0.05; ##p<0.01 compared with cells incubated with KLK1 only.CC BY · PubMed Central
Figure 9 Schematic diagram illustrating the proposed activation of PAR-4 signaling by KLK1 in tubular inflammation. Under the diabetic milieu, HG or AGE induces the expression of KLK1, which leads to PAR-4 activation, intracellular Ca2+ mobilization and phosphorylation of MAPK signaling, and results in subsequent cytokine production.
Figure 9 Schematic diagram illustrating the proposed activation of PAR-4 signaling by KLK1 in tubular inflammation. Under the diabetic milieu, HG or AGE induces the expression of KLK1, which leads to PAR-4 activation, intracellular Ca2+ mobilization and phosphorylation of MAPK signaling, and results in subsequent cytokine production.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Tang SC, Chan LY, Leung JC, Cheng AS, Lan HY, et al.. (2011) Additive renoprotective effects of B2-kinin receptor blocker and PPAR-gamma agonist in uninephrectomized db/db mice. Lab Invest. 21537328 · DOI

Cited by

Metadata

Authors
Yiu, W. H., Wong, D. W. L., Chan, L. Y. Y., Leung, J. C. K., Chan, K. W., Lan, H. Y., Lai, K. N., & Tang, S. C. W.
Affiliations
  • Queen Mary Hospital (CN)
  • Chinese University of Hong Kong (HK)
Corresponding author
Tang, Sydney C. W.
Venue
PLoS ONE
Published
2014-02-21
Volume
9
Issue
2
Pages
e88894
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2038515422
Cited by
50
References
53
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 7 · 2015: 6
FWCI
3.69
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
Funders
  • American Society of Nephrology
  • University of Hong Kong
  • National Key Research and Development Program of China (2012CB517600, 2012CB517606)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
tissue kallikrein, KLK1, diabetic nephropathy, proximal tubular epithelial cells, PAR4, kallikrein-kinin system, inflammation, high glucose, advanced glycation end products, MAPK signaling, interleukin-8, ICAM-1, interleukin-6, MCP-1, connective tissue growth factor, type IV collagen, renal fibrosis, calcium mobilization, therapeutic target
MeSH terms
Analysis of Variance, Calcium, Cells, Cultured, Diabetes Mellitus, Enzyme-Linked Immunosorbent Assay, Epithelial Cells, Humans, Immunohistochemistry, Inflammation, Kidney Tubules, Proximal, Blotting, Western, Signal Transduction, Cytokines, Interleukin-8, DNA Primers, Receptors, Thrombin, Tissue Kallikreins, RNA Interference, RNA, Small Interfering, Receptors, Proteinase-Activated, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.